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Abstract
Background: The efficacy of oxaliplatin in cancer chemotherapy is limited by the development of drug resistance. MMP7
has been related to the loss of tumor cell response to cytotoxic agents although the exact mechanism is not fully
understood. Moreover, MMP7 is an independent prognosis factor for survival in patients with colorectal cancer. The aim of
the present study was to analyze the role of MMP7 and its cross-talk with the Fas/FasL system during the acquisition of
oxaliplatin resistance in colon cancer cells.
Principal Findings: For this purpose we have developed three different oxaliplatin-resistant cell lines (RHT29, RHCT116
p53
+/+, RHCT116 p53
2/2) from the parental HT29, HCT116 p53
+/+ and HCT116 p53
2/2 colon cancer cells. MMP7 basal
expression was higher in the resistant compared to the parental cell lines. MMP7 was also upregulated by oxaliplatin in both
HT29 (p53 mutant) and RHCT116 p53
2/2 but not in the RHCT116 p53
+/+. Inhibition of MMP by 1,10-phenantroline
monohydrate or siRNA of MMP7 restores cell sensitivity to oxaliplatin-induced apoptosis in both HT29 and RHCT116 p53
2/2
but not in the RHCT116 p53
+/+. Some of these effects are caused by alterations in Fas receptor. Fas is upregulated by
oxaliplatin in colon cancer cells, however the RHT29 cells treated with oxaliplatin showed a 3.8-fold lower Fas expression at
the cell surface than the HT29 cells. Decrease of Fas at the plasma membrane seems to be caused by MMP7 since its
inhibition restores Fas levels. Moreover, functional analysis of Fas demonstrates that this receptor was less potent in
inducing apoptosis in RHT29 cells and that its activation induces MAPK signaling in resistant cells.
Conclusions: Taking together, these results suggest that MMP7 is related to the acquisition of oxaliplatin-resistance and
that its inhibition restores drug sensitivity by increasing Fas receptor. Furthermore, Fas undergoes a change in its
functionality in oxaliplatin-resistant cells inducing survival pathways instead of apoptotic signals.
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Introduction
Oxaliplatin has shown excellent efficacy in the treatment of
colorectal cancer in combination with 5-fluorouracil. Despite its
proven activity, the acquisition of drug resistance remains a major
problem in patient management, ultimately leading to patient
death [1]. Mechanisms of resistance to platinum agents such as
oxaliplatin include increased DNA repair, overexpression of
copper transporters, enhanced drug detoxification and increased
tolerance for DNA damage [2,3]. However, despite the fact that
the mechanisms influencing treatment responses are well known, it
appears that the major process leading to chemotherapy resistance
[4] is the ability of cancer cells to evade cell death signals. This loss
of response to apoptosis-induction during development of drug
resistance resembles the normal tumor progression process, in
which malignant cells also undergo molecular changes providing
them with mechanisms against cell death induction [5,6].
Fas (APO-1/CD95), a 48 kDa membrane protein belonging to
the TNF receptor superfamily, activates caspase-dependent apopto-
sis in susceptible cells when is activated by its natural ligand (FasL).
Many cancer cells acquire survival advantage during tumor
progression by decreasing its sensitivity to Fas-induced apoptosis
[6,7]. Some mechanisms affecting Fas sensitivity include downreg-
ulation of Fas protein expression [8], and blockade of the active
receptor site by the soluble formof Fas ligand (sFasL) [4], or by both.
Matrixmetalloproteinases(MMPs)arealsoimplicated inthe survival
advantage of malignant cells influencing the Fas/FasL pathway.
MMPs are zinc-dependent enzymes associated with many types
and stages of cancer. These enzymes promote metastasis and
tumor growth through a variety of mechanisms such as ECM
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immunity [9]. As a result of MMP activity tumor cells can develop
mechanisms to evade immune responses, resulting in promotion of
tumor survival, acquisition of metastatic phenotype and further
tumor dissemination [10]. MMP7 (matrilysin), is a metalloprotei-
nase with prometastatic function related to: 1) early tumor
development [11], 2) metastatic potential [12] and 3) clinical
outcome in cancer [13,14]. We have observed in patients with
advanced colorectal cancer that MMP7 is an independent
prognostic factor for shorter survival [14], probably because this
enzyme can affect tumor cell responsiveness to chemotherapy.
MMP7 has been widely studied in cancer progression not only by
its implication in ECM degradation and metastasis promotion, but
also by its role in the Fas/FasL system regulation and in the
apoptosis responsiveness of tumor cells. MMP7 modulates Fas
expression and activation, generating the soluble forms of FasL by
cleavage of its membrane form [4], and by cleaving Fas receptor
itself [8]. In both cases, induction of apoptosis by Fas activation
can be blocked by MMP7 activity.
It is well known that morphological and phenotypical
characteristics that confer tumor cells advantage against Fas-
induced apoptosis are different during tumor progression. In fact,
alterations in functional Fas status seem to be produced in parallel
to tumor progression towards a more metastatic phenotype [6,15].
In CRC cell lines different metastatic subpopulations pre-exist
within the heterogeneous primary cells. It is known that these cell
subpopulations are resistant to Fas-induced apoptosis and that the
selective pressure that favours the outgrowth of these metastatic
cells selects also for populations with altered Fas functionality [15].
However, loss of Fas expression and functionality during tumor
progression is not the unique mechanism accounting for the
acquisition of apoptosis resistance. Increased MMP7 expression
also contributes to the selection of cells with reduced sensitivity to
Fas-induced apoptosis [8,13,16], to drug cytotoxicity [4], and to
changes in the metastatic phenotype. The apoptotic-effects of
some cytotoxic agents such as doxorubicin are mediated by
upregulation of Fas and FasL expression, and by activation of the
apoptotic signalling in the neighbouring cells [4]. Regarding this,
MMP7 can protect cells against death by cleavage of both Fas
receptor and its ligand from the cell surface, reducing the
effectiveness of FasL in triggering apoptosis [4,8,13,16].
In the present work, we demonstrate that MMP7 expression
increases when tumor cells acquire resistance to oxaliplatin. The
inhibition of MMPs restores cell sensitivity either with a chemical
inhibitor or with inhibition of MMP7 by siRNA, in part by
increasing the levels of Fas receptor at the cell surface. One
mechanism by which oxaliplatin induces cell death is by Fas
upregulation, as previously described for other cytotoxic drugs [4].
However, we have observed that in resistant cells the upregulation
of Fas expression by oxaliplatin is partially blunted. Moreover, in
these cells Fas, which normally activates apoptotic pathways,
switches its function and induces the expression of survival
proteins.
Results
MMP7 is related to the acquisition of resistance to
oxaliplatin in colon cancer cells
Some authors have observed that addition of MMP7 to cell
cultures protects cells from drug cytotoxicity [4] and from
cytotoxic T-cell killing [8], but whether MMP7 exerts these effects
physiologically or if its expression is related to the acquisition of
drug resistance remains unresolved. To analyze the role of MMP7
in these processes, we first generated cell lines resistant to
oxaliplatin treatment by exposure of the parental cells to the drug
over 5 months. These oxaliplatin-resistant cells show an IC50
several fold higher (RHT29 80 mM, RHCT116 p53
+/+ ,8 mM
and ,15 mM RHCT116 p53
2/2) than the parental (HT29 ,5–
7 mM, HCT116 p53
+/+ ,1.75 mMa n d,2 mM HCT116 p53
2/2),
asdeterminedbyMTSassay(Figure1A),andtheyaremoreresistant
to oxaliplatin induced apoptosis (Figure 1B), as analyzed by
annexin/IP staining (5-fold double staining for HT29 compared to
2-fold double staining for RHT29). We chose the HT29 normal and
resistant cells for the in vivo experiments since they shown the most
resistant phenotype. In vivo, RHT29 also shows resistance when the
drug is administered as a single dose of 10 mg/kg once a week for 4
weeks (Figure 2A). Moreover, characterization of their growth
dynamics and their colony formation properties show that, although
resistant cells can grow under drug treatment, its growing rate is
much lower compared to non-resistant cells (Figure 2B), in
agreement with other studies [17]. This lower growth rate was also
observed in vivo (Figure 2A). On the other hand, the RHT29 cell line
shows phenotypic changes consistent with a more mesenchymal
phenotype, as it was observed by increased intercellular separation,
spindle-shape morphology and formation of pseudopodia (not
shown), as previously described for this model of chemoresistance
[17].
We determined MMP7 expression in these cell lines and we
observed that this protease was upregulated in the RHT29 (p53
mutated) and HCT116 p53
2/2 cell lines but not in HCT116
p53
+/+ cell line, as we observed by immunocytochemistry and by
qPCR (Figure 3A and 3B). In the case of the HT29 and RHT29
cells, we performed an ELISA from the supernatants and found
also increased levels of MMP7 secretion in the resistant cells (not
shown). Interestingly, it was noticed that treatment with oxaliplatin
increases the expression of MMP7 in the RHT29 and HCT116
p53
2/2 cell lines but not in HCT116 p53
+/+ cell line (Figure 3A
and 3B) and in the xenografts of HT29 and RHT29 cells
(Figure 3C), suggesting that p53 status is related to the
upregulation of MMP7 expression in these cell lines.
These results demonstrate that MMP7 expression increases
during the acquisition of resistance to oxaliplatin in CCR cell lines,
and that this protease could also be upregulated by oxaliplatin
treatment.
MMP7 influences the response of tumor cells to
oxaliplatin-induced cell death
We next investigated whether higher MMP7 expression
correlates with loss of cell responsiveness to the drug. For this
reason, we inhibit MMP7 by siRNA-directed silencing of this
protease. We transfected cells with three different oligonucleotides
of siRNA that resulted in decrease of MMP7 mRNA levels by
.80% (not shown). Specific inhibition of MMP7 sensitizes the
RHT29 and HCT116 p53
2/2 cell lines to oxaliplatin-induced cell
death (Figure 4A), in agreement with previous reports [4].
However, HCT116 p53
+/+ cell line was not affected by the
inhibition of MMP7 (Figure 4A). On the other hand, treatment of
HT29 cells with 5 ng/ml of rhMMP7 enzyme also protected cells
against oxaliplatin-induced cell death, as we observed in a MTS
assay (Figure 4B) and by annexin V/IP staining (Figure 4C).
Because no specific inhibitor of MMP7 exists, we used the
MMP inhibitor 1,10-phenantroline monohydrate (referred to
hereafter as inhibitor) in additional experiments. Considering that
the use of this inhibitor itself may cause cell toxicity, we previously
determined by MTS assay and by annexin V/IP staining at which
dose we had the lower cell toxicity (not shown). Inhibition of
MMPs with 5 mM of 1,10-phenantroline monohydrate restores
sensitivity of RHT29 cell line to the drug (Figure 4D).
MMP7 and Chemoresistance
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drug since its inhibition is sufficient to restore the response to the
treatment.
Oxaliplatin fails to overexpress Fas receptor in cells
resistant to the drug
The observation that MMP7 levels increase when cells become
resistant to oxaliplatin and that its expression is regulated by the
drug, led us to consider that the membrane expression of Fas
receptor and its ligand (FasL) was influenced by MMP7
expression. It is well known that Fas and FasL are MMP7
substrates [8,18], therefore alterations in MMP7 may be directly
related to changes in the Fas/FasL system. We decided to measure
Fas and FasL expression at the cell surface of HT29 and RHT29
cells by FACS analysis and determine if their expression correlated
with MMP7 inhibition. Since MMP7 seems to be the most
important protease related to the cleavage of Fas and FasL, we
used MMPs inhibitor for the next set of experiments assuming that
the effects of this inhibitor in other proteases would be less
significant. Regarding Fas expression, oxaliplatin increases the cell
surface form of Fas in both cell lines (Figure 5A) similarly to other
cytotoxic agents that activate apoptotic pathways by Fas
upregulation [5,19]. However, this increase was significantly lower
in the resistant cells (0.6-fold) than in the non-resistant ones (2.3-
fold), which suggests that Fas protein levels, as the detected by the
DX2 antibody, could be blocked in the RHT29 cell line. To
confirm that these alterations in Fas expression were produced at
the level of the plasma membrane, we determined the localization
of the receptor in cell microarrays of HT29 and RHT29 treated
with oxaliplatin for 24 hours. In this case, Fas was also upregulated
by oxaliplatin in the normal cells, while resistant cells remained
unaltered (Figure 5B). Fas expression at the cell surface can be
modulated by MMP7 in a direct way (by cleavage of the receptor)
[8] or indirectly by upregulation of soluble forms of FasL which
can block Fas [4]. In our case, when MMPs were inhibited by
1,10-phenantroline monohydrate, the levels of Fas at the cell
surface were similar in both cell lines (Figure 5A), suggesting that
higher levels of MMP7 in RHT29 cells may be responsible for the
lower receptor levels in the resistant cells.
To determine if Fas was lower on the cell surface of RHT29
cells because of lower rate of transcription, we determined the
mRNA content of Fas in both cell lines cultured with or without
the drug. Surprisingly, we observed that oxaliplatin increases
mRNA expression of Fas in normal and resistant cells both in vitro
Figure 1. Characterization of cell lines resistant to oxaliplatin-induced cell death. A) Non-resistant (HT29, HCT116 p53
+/+, HCT116 p53
2/2)
and resistant cells (RHT29, RHCT116 p53
+/+, RHCT116 p53
2/2) were assessed by MTS for its response to oxaliplatin treatment. The dose-response
curve shows a higher IC50 for the resistant cell lines than for the parental cells as expected. Results are represented as mean6SEM for 6 samples in
each group. B) HT29 and RHT29 cell lines were treated or not with oxaliplatin at 10 mM for 48 hours and apoptosis induction was detected by
Annexin V/IP staining. These are representative graphics of 3 samples per group, showing less apoptotic induction in the RHT29 cell line. OXA:
oxaliplatin.
doi:10.1371/journal.pone.0004728.g001
MMP7 and Chemoresistance
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Although Fas expression has been related to p53 status by several
authors [20,21], these effects were independent of p53 since both
cell lines were mutated for the protein. This was confirmed in the
HCT116 p53
+/+ and HCT116 p53
2/2 cell lines, where we also
observed a stronger induction of Fas mRNA by oxaliplatin
treatment, mainly in the HCT116 p53-null cells (Figure 5D).
These results suggest that, although oxaliplatin upregulates Fas
mRNA in HT29 and RHT29 cells in a similar way, the detection
of the receptor at the cell surface was lower in the resistant cells
because higher MMP7 expression.
FasL expression is also upregulated by oxaliplatin
treatment but decreased in the plasma membrane of
resistant cells
We next determined the expression of FasL, a molecule known
to be cleaved and released from the cell surface by MMP7 [4]. The
analysis of FasL expression under oxaliplatin treatment shows that
the drug does not increase significantly the expression of FasL at
the cell surface of both cell lines (Figure 6A). However, the mRNA
content of FasL was strongly upregulated in both cells lines by
oxaliplatin treatment, being these effects more pronounced in the
resistant cell line (20-fold) than in the normal one (4-fold)
(Figure 6B). It has been observed in other cell lines that cytotoxic
treatment could induce FasL expression by upregulation of the
NF-kB system. To determine if this system was altered in our
model, we decided to analyze the expression of the p65 subunit by
using an antibody that recognizes the nuclear localization signal
(NLS), an epitope that could be detected when p65 is activated
[22]. The expression of NLS-p65 was similar in both cell lines, but
under oxaliplatin treatment its activation was higher in the
resistant cell line (Figure 6C). Moreover, RHT29 cells showed
higher sensitivity to the inhibition of the NF-kB pathway by the
IKK inhibitor Bay117085 (Figure 6D) than the non-resistant cells,
indicating a metabolic dependence on this pathway by the
resistant cell line. Therefore, the increased expression of FasL is
correlated with the increased activation of the NF-kB system.
These results suggest that, although oxaliplatin treatment induces
the synthesis of FasL in both cell lines, its detection at the cell
surface is not increased by the drug treatment probably by the
shedding of FasL by MMP7.
Acquisition of resistance to oxaliplatin causes a change in
the functionality of Fas receptor
The lower upregulation of Fas by oxaliplatin at the cell surface
of RHT29 led us to consider the possibility of this being one of the
mechanisms by which tumor cells avoid drug-induced apoptosis.
Besides the levels of expression of the receptor at the cell surface, it
has also to be considered its innate function as death receptor. In
order to analyze the functionality of the Fas receptor, we
determined the induction of apoptosis by the agonistic antibody
CH11 when cells were treated with oxaliplatin or with the
Figure 2. Analysis of HT29 and RHT29 growth rate. A) HT29 and RHT29 cells were subcutaneously inoculated into nude mice. Two weeks later,
animals were treated with oxaliplatin 10 mg/kg once a week for 27 days. Results illustrate tumor volume and are represented as mean6SEM for 10
animals per group. The lower panel is a representative image of tumors obtained from animals treated or not with oxaliplatin. B) Growth kinetics was
studied by colony formation assay. This representative image shows that HT29 cells are not able to grow under oxaliplatin treatment compared to
RHT29 cell line. However, HT29 cells have a higher clonogenic capacity than RHT29 after 21 days of growth. OXA: oxaliplatin.
doi:10.1371/journal.pone.0004728.g002
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antibody was undetectable in both cell lines according to previous
studies reporting that stimulation of Fas requires previous
activation (Figure 7A, 7B). Interestingly, activation of Fas receptor
by the agonistic antibody CH11 when cells where treated by both
oxaliplatin (Figure 7A) and MMP inhibitor (Figure 7B) was
significantly blunted in the resistant cell line (3-fold and 2-fold
lower induction for oxaliplatin and MMP inhibitor treatment,
respectively), suggesting that in addition to the lower expression of
the receptor in RHT29 cells, it is also less potent in activating
apoptotic pathways.
Since it has been proposed that Fas can activate other targets
and can exert other functions besides apoptosis and, that its
activation in some cell lines can have tumor-promoting effects
[23], we asked if Fas was inducing survival pathways instead of
activating cell death. To address directly this question, we
analyzed the levels of phosphorylated and total amount of p42/
44 MAPK and p38 MAPK after activation of Fas by CH11 in
both cell lines. As it is shown in Figure 7C, activation of Fas by
CH11 lead to a higher upregulation of these proteins in the
resistant cell line compared to the non-resistant cells, pointing to a
change in the functionality of the receptor in cells that have
acquired resistance to apoptosis-induction by oxaliplatin.
Discussion
MMP7 is widely expressed in human cancer [24] and in tumor
cell lines [25]. Its expression has been correlated with tumorige-
nicity [26], with clinical aggressiveness of different tumor types
[14,27,28], and to loss of response to chemotherapeutic drugs in
vitro [4,16]. However, these reports are based on studies aimed at
inducing or inhibiting gene expression, which may not reflect the
real physiological situation. In this report, we demonstrate that
upregulation of MMP7 expression is a direct result of the
acquisition of resistance to oxaliplatin, supporting its role in the
development of drug-resistance. During the generation of resistant
cell lines, only few clones may survive each round of therapy,
suggesting that inside the heterogeneous tumor cell population
only cells with high expression of MMP7 survive. These results are
consistent with the findings reported by others, where it was
observed that exogenous addition of MMP7 also increases
resistance to drug-induced cytotoxicity [4]. Furthermore, since
MMP7 seems to promote tumor survival, it is interesting to note
that oxaliplatin treatment also induces MMP7 expression both in
normal as well as in resistant cells. This implies a paradoxical effect
since a treatment directed to activate apoptotic pathways also
induces the expression of proteins that protect cells from death.
Figure 3. MMP7 shows a higher expression in the oxaliplatin resistant cell lines. A) Immunofluorescence (IF) staining of MMP7 in the non-
resistant (HT29, HCT116 p53
+/+, HCT116 p53
2/2) and resistant cells (RHT29, RHCT116 p53
+/+, RHCT116 p53
2/2). MMP7 is strongly upregulated in the
RHT29 and RHCT116 p53
2/2 cell lines and its expression is also increased by oxaliplatin treatment. Levels of MMP7 were also analyzed by qPCR both
in vitro (B) and in vivo (C) obtaining a similar pattern than in the IF assay. Results represent the mean6SEM for 6 samples in each group. Values that
are significantly different between control and treated group by ANOVA analysis are indicated by *p,0.05,**p,0.001,***p,0.0001, and between
different cell lines {{{p,0.0001. OXA: oxaliplatin.
doi:10.1371/journal.pone.0004728.g003
MMP7 and Chemoresistance
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+/+ cell line
suggest that upregulation of MMP7 is dependent on p53 status.
One of the mechanisms by which MMP7 protects cells is by
favouring the shedding of FasL from cell surface and increasing
the proportion of sFasL available to bind Fas [4]. From the results
of this work it can be proposed that MMP7 protects cells against
Fas-induced cell death by a similar pathway, by cleaving FasL and
increasing sFasL, but also by cleaving Fas and decreasing the
number of receptors at the plasma membrane. However, it is
important to note that during the acquisition of resistance to
oxaliplatin a positive loop evolves where the treatment itself
upregulates MMP7 (Figure 8). From this point of view, the NF-kB
system, which is activated in the oxaliplatin-resistant cells, is also
playing a tumor-promoting role regulating FasL synthesis.
However, it has to be considered that in these cells Fas is not
activating the apoptotic pathways, but promoting pathways related
to cell survival and migration. Therefore, it can be suggested that
this positive loop generated by oxaliplatin treatment could, at the
end, promote tumor progression by Fas activation and induction
of tumor-promoting pathways (Figure 8). We are currently testing
this hypothesis experimentally.
This relationship between MMP7 and Fas activation could also
have implications during tumor progression. The involvement of
MMP7 in the promotion of a tumor in its early stages has been
discussed by several authors [29,30]. It has been proposed that
MMP7 expression in the first steps of tumorigenesis will select cells
with reduced sensitivity to Fas-induced apoptosis [29]. In these
stages the sFasL generated by MMP7 could activate apoptosis,
allowing the survival of cells that do not activate apoptosis via Fas
[4]. These selective effects of MMP7 during tumor progression are
similar to those observed during the acquisition of chemoresis-
tance. Therefore, the mechanism of oxaliplatin selection could be
mediated by a similar pathway, favouring the selection of cells
where Fas activation does not induce apoptosis.
The changes in Fas functionality could have implications
regarding FasL functionality. The role of sFasL as a pro- or
antiapoptotic stimulus has been largely controversial, but based on
the results obtained by us and others [6] it can be proposed that
effects of FasL do not depend on its origin (soluble or membrane
form) but in the responsiveness of Fas upon activation. Fas
expression decreases during tumor progression [31,32,33], and
many cancer cells acquire a survival advantage by decreasing its
Figure 4. Inhibition of MMP7 by siRNA or addition of rhMMP7 modulates cell response to oxaliplatin-induced apoptosis. A) MMP7
expression was inhibited by siRNA and then treated with different doses of oxaliplatin in order to analyze the effects of MMP7 inhibition in the
response to oxaliplatin treatment. Cell viability was then assessed by MTS assay. To analyze the protective effects of MMP7 cells were treated with
rhMMP7 (5 ng/ml) and with different doses of oxaliplatin. The effects on cell viability were determined by B) MTS or C) by annexin V/IP staining. D)
The effects of MMPs inhibition on cell survival were determined in HT29 and RHT29 cells treated with 1,10-phenantroline monohydrate and then with
different doses of oxaliplatin. It can be observed that cells response equally to oxaliplatin when MMPs are inhibited. Results are the mean6SEM for 3
samples per group. Values that are significantly different between control and treated group by ANOVA analysis are indicated by ***p,0.0001. OXA:
oxaliplatin.
doi:10.1371/journal.pone.0004728.g004
MMP7 and Chemoresistance
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survival pathways by Fas engagement has been previously described
[23], this is the first report to our knowledge that demonstrates that
acquisition of resistance to a cytotoxic drug also induces the loss of
ability of Fas to induce apoptosis. Therefore, FasL effects will
depend of the molecular pathways activated by Fas.
During tumor progression cells can acquire survival advantages
by decreasing Fas expression [31,32,33] and its sensitivity to Fas-
induced apoptosis [7]. In fact, Fas activation by FasL in cell lines
resistant to apoptosis increases motility and invasiveness [23]. In
this work, we have demonstrated, to our knowledge, for the first
time that when colon cancer cells acquire resistance to oxaliplatin
a change in Fas functionality develops, and a receptor switch
occurs: from activation of apoptosis to stimulation of MAPK
pathways. Therefore, it can be suggested that once the cells have
acquired resistance to oxaliplatin, continuous exposure to the drug
may favor cell survival by increasing the expression of MMP7 and
by activation of Fas, which is regulating cell survival and migration
pathways.
Materials and Methods
Cell lines and reagents
Human colon carcinoma cell line HT29 was purchased from
American Type Culture Collection (Rockville, MD). HCT116
p53
+/+ and HCT116 p53
2/2 were generously given by Dr.
Vogelstein. The oxaliplatin-resistant cell lines (RHT29,
RHCT116 p53
+/+, RHCT116 p53
2/2) were developed by
repeated exposure of parental cells to increasing concentrations
of oxaliplatin over a 5-month period. Experiments were performed
with the resistant population obtained from this process instead of
using clones to better mimic the normal process by which a patient
develops chemoresistance. During the process, cell mortality was
assessed for several days and the few cells that survive were
recultured in 2.5-cm diameter dishes until they recovered their
growth rate. All cell lines were routinely cultured in McCoy’s
Medium supplemented with 10% heat inactivated foetal bovine
serum, antibiotics (Gibco, Invitrogen), and in the case of the
resistant cells, with a minimum concentration of oxaliplatin to
ensure the development of a resistant population. The cultures
were incubated at 37uC in a humidified 5% CO2 atmosphere and
the cells were serum starved overnight before experiments.
Antibodies used were mouse monoclonal anti-FasL (clone
NOK-1) and mouse monoclonal anti-Fas (clone DX2) both from
Pharmingen; mouse monoclonal anti-Fas (clone CH11) from
Upstate Biotechnology; mouse monoclonal anti-MMP7 (clone
ID2) from Abcam; mouse monoclonal anti-NF-kB (NLS epitope)
from Chemicon, rabbit polyclonal antibodies against phospho-
p42/44 MAPK, p42/44 MAPK, phospho-p38 MAPK and p38
MAPK, were from Cell Signaling Technology, and mouse
Figure 5. Modulation of cell surface Fas expression in HT29 and RHT29 cell lines. To analyze the expression specifically in the plasma
membrane, Fas receptor was determined by A) FACS analysis or B) by immunohistochemistry in a cell line microarray, as described in Materials and
Methods. Fas mRNA expression under oxaliplatin treatment was also determined C) in vitro and in vivo for the HT29 and RHT29 cell lines, D) and also
in vitro for the HCT116 p53
+/+ and HCT116p53
2/2 cell lines. Results are represented as mean6SEM for 5 samples per group in the in vitro experiments
(C and D) and for 10 animals per group in the in vivo determinations (C). Values that are significantly different between control and treated group by
ANOVA analysis are indicated by *p,0.05,**p,0.001,***p,0.0001. INH: inhibitor (1,10-phenantroline monohydrate), OXA: oxaliplatin.
doi:10.1371/journal.pone.0004728.g005
MMP7 and Chemoresistance
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phenantroline monohydrate was purchased from Sigma, and
IKK inhibitor Bay117085 was from Calbiochem. Oxaliplatin was
from Sigma. All general reagents were purchased from Sigma,
Bio-Rad and Amersham.
Cell viability assay
Cell viability was assessed in subconfluent cell cultures that
were incubated for 72 hours with different treatments: oxalipla-
tin, 1,10-phenantroline monohydrate or both. In the experiments
designed to analyze the effects of rhMMP7 (recombinant human
MMP7, Chemicon), cells were pretreated with 5 ng/ml of this
protease for 24 hours, and then treated with oxaliplatin at
different concentrations for 72 hours. Briefly, cells were seeded in
96-well plates at a density of 5.000 cells/well and allowed to
attach overnight. After treatment, cells were monitored daily
under microscope and cell viability was determined with a
tetrazolium compound by CellTiter 96 Aqueous One Solution
Cell Proliferation Assay Kit (MTS, Promega), according to the
manufacturer’s instructions. For colour development, 20 mlo f
MTS were added to each well and then the plate was read on a
microplate spectrophotometer (Molecular Dynamics) at 490 nm
(test wavelength) and 690 nm (reference wavelength). Different
doses were assessed in sixtuplicate and every experiment was
done in triplicate. Assay values for controls were taken as 100%
of viability, and the viability at each treatment point was
calculated relative to controls by the formula: (Abs 490 nm at
every dose/Abs 490 nm at dose 0)6100%.
Figure 6. Modulation of FasL expression in HT29 and RHT29 cells lines. FasL expression was detected in HT29 and RHT29 cell lines treated
or not with oxaliplatin 10 mMb yA) FACS analysis of its surface expression or B) qPCR of its mRNA levels. C) NF-kB p65 was detected by Western Blot
by the use of an antibody that recognizes the nuclear localization signal (NLS) epitope. Tubulin expression was used as endogenous control. D)
Sensitivity of both cell lines to the inhibition of the NF-kB pathway was measured by an MTS assay in which cells were treated with different doses of
BAY117085, a known inhibitor of IKK activation. Values that are significantly different between control and treated group by ANOVA analysis are
indicated by ***p,0.0001. OXA: oxaliplatin.
doi:10.1371/journal.pone.0004728.g006
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For the detection of MMP7 expression, cells were seeded in
coverslips until subconfluence and treated with the IC50 for
oxaliplatin obtained in each cell line (5 mM, 1.75 mM and 2 mM
for HT29, HCT116 p53
+/+ and HCT116 p53
2/2, respectively)
for 72 hours. Then, cells were washed twice with cold Hepes
Buffered Saline buffer (HBS buffer: 135 mM NaCl, 10 mM KCl,
0.4 mM MgCl2, 1 mM CaCl2, 10 mM Na-Hepes pH 7.4), fixed
for 15 min with 4% paraformaldehyde at 4uC, followed by 6 min
in methanol at 220uC. After two washes with HBS, cells were
blocked for 20 min with 1% of BSA on cold PBS and then
incubated with primary antibody against MMP7 overnight at 4uC.
Control samples were incubated with buffer or non-specific
purified mouse immunoglobulin G. Then, coverslips were washed
twice with HBS buffer and incubated for 1 hour at room
temperature with anti-mouse secondary antibody labelled with
Alexa 594 (Molecular Probes, Invitrogen). After staining, the
coverslips were mounted on glass slides with Mowiol (Calbiochem)
and viewed using an inverted epifluorescence microscope (Leica).
Image assembly and processing were performed using the Image
Processing Leica Confocal Software at the Microscopy Unit of the
School of Medicine of the University of Barcelona.
Paraffin-embedded cell arrays and Fas
immunohistochemistry
The paraffin-embedded cell line microarray was generated as
previously described [34]. Briefly, after trypsinization cells were
fixed in 4% paraformaldehyde, washed with PBS and centrifuged.
Then, the cell pellet was mixed with 100 ml of melted agar and
after its solidification the agar plugs were processed for paraffin
embedding as regular biopsies. The blocks obtained were used to
construct the cell line array using a tissue microarrayer (Beecher
Instruments) and a 2-mm-gauge needle.
Array sections of two micrometer thickness were placed on
slides and used for Fas immunohistochemistry with the monoclo-
nal anti-Fas antibody DX2.
In vivo experiments
Animal experiments were performed in accordance with the
regulations of our institution’s ethics commission, following the
guidelines established by the government of Catalonia, Spain.
Twenty female athymic nude mice (Harlan), 4–5 weeks old were
used in this study. The mice were bred at the Medical School
animal facility laboratory and kept under specific pathogen-free
conditions at constant ambient temperature (22–24uC) and
humidity (30–50%). The mice were given sterilized food and tap
water ad libitum.
To produce colon carcinoma xenografts, HT29 and RHT29
cells were grown to 80% confluence and trypsinized. Cell viability
was confirmed by trypan blue exclusion. Only suspensions
consisting of single cells with .90% viability were used for
subcutaneous (s.c.) injection of 2610
6 cells in 50 ml of PBS in
mouse left flank. Treatment began 2 weeks after inoculation, with
mice bearing ,100-mm
3 subcutaneous tumors. Groups of mice
(each group n=10) were randomly assigned to receive one of the
following treatments: a) Intraperitoneal (i.p.) injection of saline
solution once a week (control group), b) administration i.p. of
oxaliplatin 10 mg/kg once per week during 27 days. Tumors were
measured twice per week with a caliper square and, their volumes
calculated by the formula: (a6b
2)/2, where a and b are the larger
and the smaller diameter, respectively. At the end of treatments
animals were sacrificed and the tumors removed, minced, placed
into liquid nitrogen and stored at 280uC.
qRT-PCR Analysis
Total RNA from tumor cells was isolated with Ultraspec
(Biotecx) according to the manufacturer’s instructions. Approxi-
mately 1 mg of total RNA was reverse-transcribed into cDNA
using the Archived Kit (Applied Biosystems). Negative controls,
Figure 7. Analysis of the different pathways activated by Fas in
HT29 and RHT29 cells. To determine the ability of Fas to induce cell
death, cells were treated or not with A) oxaliplatin and B) MMP
inhibitor for 24 hours, and then apoptosis was induced by the addition
of the agonistic antibody CH11 at a final concentration of 150 ng/ml.
Apoptosis induction by Fas activation was determined by annexin V/IP
staining as described in Materials and Methods. Results are represented
as arbitrary units assuming that control value is 1 and are mean6SEM
for 3 samples per group. C) Activation of MAPK pathways in cells
treated or not with 150 ng/ml of CH11 for 24 hours was detected by
Western blot analysis. Tubulin expression was used as an endogenous
control. Values that are significantly different between control and
treated group by ANOVA analysis are indicated by *p,0.05,
**p,0.001, ***p,0.0001. OXA: oxaliplatin.
doi:10.1371/journal.pone.0004728.g007
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to confirm the absence of genomic DNA contamination.
Quantitative PCR analysis was done on the ABI PRISM 7900
Sequence Detector System (Applied Biosystems). For determina-
tion of gene expression Assay-on-demand (Applied Biosystems)
was used (Hs00159163_m1 for MMP7, Hs00181225_m1 for
FasL, Hs_00531110_m1 for Fas), which consist of a 6-FAM dye-
labeled TaqMan MGB probe and the corresponding unlabeled
primers. The PCR reaction mixture consisted of 5 mM of each
primer, 10 ml of master mix (TaqMan Universal PCR Master
Mix, Applied Biosystems) and 2 ml of cDNA. Transcript levels
were normalized to those of beta-actin (Hs99999903_m1), which
was used as endogenous control. Each experiment and every
determination were done at least in triplicate, and the levels of
MMP7, Fas and FasL were calculated using the DDCt method.
Transfection with antisense MMP7
Silencing of MMP7 was done by Stealth RNAi technology from
Invitrogen, which provides three different chemical modified
oligonucleotides against three different regions of the RNA target.
Before silencing experiments, the protocol was adjusted to ensure a
minimum of 80% of RNA knockdown assessed by qPCR.
According to the manufacturer’s instructions cells in a 96 multiwell
plate were reverse transfected with Lipofectamine RNAiMAX and
20 nM of each stealth, and 24 hours latter cells were treated with
different doses of oxaliplatin as mentioned before. Cell viability
was determined after 72 hours by MTS assay. For negative
controls, cells were treated with lipofectamine alone or with a GC
control (Invitrogen).
Cytometric determinations
Determinations of cell surface Fas and FasL
expression. For the detection of cell surface Fas and FasL
expression, cells were treated with oxaliplatin (10 mM), 1,10-
phenantroline monohydrate (5 mM) or both for 72 hours. Then,
cells attached to the plate and from the supernatants were washed
with PBS, resuspended in blocking buffer (BSA 1%-PBS) and
placed on ice for 30 min. Cell surface staining of tumor cells was
done with the following primary monoclonal antibodies: anti-Fas
mAb (clone DX2) or anti-FasL mAb (clone NOK1) in blocking
buffer for 1 h at 4uC. Cells were then washed 3 times with
BSA1%-PBS and stained with FITC-conjugated anti-mouse IgG
antibody for 1 hour at 4uC. Control cells without staining were use
to determine the settings of autofluorescence, and cells stained
with secondary antibody were used to ensure the specificity of the
primary antibodies. Stained cells were then analyzed on a
FACscan flow cytometer using FACSCalibur (BD Biosciences)
and data processed by the software CellQuest. Twelve thousand
cells were analyzed for each sample, and every experiment was
performed in triplicate. Results are expressed in arbitrary units
Figure 8. Mechanism of acquisition of resistance to oxaliplatin-induced cell death. A) In a tumor with low levels of MMP7 oxaliplatin is
able to induce an upregulation of Fas receptor at the plasma membrane (1), allowing its activation by cells expressing FasL, such as cytotoxic cells or
the surrender cells of the tumor (2). B) On the other hand, in cells with higher levels of MMP7, such as cells that have acquired resistance to
oxaliplatin, the activation of Fas receptor is different. Oxaliplatin in these cells induce a stronger upregulation of FasL (1) that is shaded by MMP7 to
generate sFasL (2). This sFasL binds to Fas probably inducing its activation (3). Fas receptor could, in turn, be shaded by MMP7, decreasing the
availability of Fas at the cell surface (4), although the remaining Fas receptor could be activated by its ligand inducing pathways related to cell
survival.
doi:10.1371/journal.pone.0004728.g008
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of each treatment/fluorescence of control cells).
Annexin V/IP staining. For the characterization of
oxaliplatin resistance HT29 and RHT29 cells were seeded in 6-
well tissue culture plates, allowed to attach overnight and
subsequently cultured in medium containing oxaliplatin (10 mM)
for 48 hours. For the analysis of apoptosis induction, cells were
seeded as mentioned before and treated with oxaliplatin (10 mM),
1,10-phenantroline monohydrate (5 mM) or both for 24 h. Then,
cells were treated with the Fas-activating antibody CH11 for
additional 48 h. To determine the protective effects of MMP7
against oxaliplatin-induced apoptosis cells seeded in 6-well tissue
culture plates were treated with rhMMP7 5 ng/ml for 24 hours
and then treated with oxaliplatin (10 mM) for additional 24 hours.
In all studies apoptosis was determined using Annexin-V-FLUOS
Staining Kit (Roche), according to the manufacturer’s instructions.
Briefly, cells from the culture supernatants and those attached to
the plate were blocked for 30 min with 1% of albumin and then
incubated for 15 min with Annexin V-FITC and propidium
iodide (PI). Controls (binding buffer only, PI only, and annexin-V
only) were used to set appropriate detector gains, compensation,
and quadrant gates in the FACSCalibur flow cytometer. Twenty
thousand cells for each sample were analyzed by the CellQuest
software. Every experiment was performed in triplicate
Western blot
The determinations of the total and activated forms of Erk 1/2
and p38 MAPK and the activated form of NF-kB were performed
by Western blotting analysis as previously described [35] in cells
treated with CH11 (150 ng/ml) for 24 hours. Tubulin expression
was used as an endogenous control.
ELISA
MMP7 was determined using a quantitative solid phase
sandwich enzyme-linked immuno sorbent assay (ELISA) (R&D
Systems) as previously described [14] and tested in duplicate. The
ELISA for MMP7 can detect both the pro- and active forms of
recombinant human MMP7. High concentrations of MMP7 were
diluted with calibrator, to produce samples with values within the
dynamic range of the assay.
Colony Formation Assay
For colony formation assay, cells were plated at 500 cells/plate
in 6 cm diameter cell culture dishes, treated with oxaliplatin (1.5
and 2 mM) and allowed to grow at 37uC. After 21 days, colonies
were stained with crystal violet (Sigma) and scanned to obtain
representative images. The experiments were performed in
triplicate.
Statistical analysis
Statistical analysis of the results was performed by ANOVA and
Kurskal-Wallis analysis. Statistical significance was considered for
p values less than 0.05.
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